Close menu

Promega research published in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers. The molecule, called SJ3149, demonstrates potent anti-proliferative activity in a variety of human cancer cell lines through selective degradation of the cancer-causing protein CK1α. The authors suggest that this degrader shows great promise for broad-spectrum anti-cancer applications.


READ THE publication IN Nature


More information